Treatment options from bench to bedside for adult dermatomyositis

References

• Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;373:393–394.
   PubMed Web of Science ®Google Scholar
• Shinjo SK. Systemic autoimmune myopathies. Rev Paul Rheumatol. 2017;16:6–11.
   Google Scholar
• Lundberg IE, Tjamlund A, Bottai M, et al. European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(2271–82):2017.
   Google Scholar
• Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:201–212.
   Web of Science ®Google Scholar
• Greenberg SA. Inflammatory myopathies: evaluation and management. Semin Neurol. 2008;28:241–249.
   PubMed Web of Science ®Google Scholar
• Wolstencroft PW, Fiorentino D. Dermatomyositis and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28.
   PubMed Web of Science ®Google Scholar
• Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;CD003643.
   Google Scholar
• Leclair V, Lundberg IE. Recent clinical trials in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2017;29:652–665.
   PubMed Web of Science ®Google Scholar
• De Souza FHC, De Araújo DB, Vilela VS, et al. The Brazilian society of rheumatology recommendations on investigation and diagnosis of systemic autoimmune myopathies. Adv Rheumatol. 2019;59:42.
   PubMedGoogle Scholar
• De Souza FHC, De Araújo DB, Vilela BS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol. 2019;59:6.
   PubMedGoogle Scholar
• De Moraes MT, De Souza FH, De Barros TB, et al. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken). 2013;65:793–799.
   PubMed Web of Science ®Google Scholar
• Silva MG, Borba EF, Mello SB, et al. Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients. Clinics. 2016;71:7–14.
   Web of Science ®Google Scholar
• Borges IBP, Shinjo SK. Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies. Rheumatol Int. 2019;39:311–316.
   PubMed Web of Science ®Google Scholar
• Souza FH, Barros TB, Levy-Neto M, et al. Adult dermatomyositis: experience of a Brazilian tertiary care center. Rev Bras Reumatol. 2012;52:897–902.
   PubMedGoogle Scholar
• Marie I, Mcnard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum. 2011;41:48–60.
   PubMed Web of Science ®Google Scholar
• Shinjo SK, de Moraes JC, Levy-Neto M, et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease. Vaccine. 2012;31:202–206.
   PubMed Web of Science ®Google Scholar
• Davis JS, Currie BJ, Fisher DA, et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell Q Rep. 2003;27(4):526–532.
   PubMedGoogle Scholar
• Bruhler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.
   PubMed Web of Science ®Google Scholar
• De Souza FH, Shinjo SK, Yamakami LY, et al. Reduction of ovarian reserve in adult patients with dermatomyositis. Clin Exp Rheumatol. 2015;33:44–49.
   PubMed Web of Science ®Google Scholar
• Missumi LS, Souza FH, Andrade JQ, et al. Pregnancy outcomes in dermatomyositis and polymyositis patients. Rev Bras Reumatol. 2015;55:95–102.
   PubMed Web of Science ®Google Scholar
• Souza FHC, Araújo DB, Silva CA, et al. Analysis of sexual function of patients with dermatomyositis and polymyositis through self-administered questionnaires: a cross-sectional study. Rev Bras Reumatol. 2017;57:134–140.
   Google Scholar
• Gupta L, Lawrence A, Edavalath S, et al. Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis. Int J Rheum Dis. 2018;21:725–731.
   PubMed Web of Science ®Google Scholar
• De Andrade DC, De Magalhães Souza SC, De Carvalho JF, et al. High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis. Rheumatol Int. 2012;32:1549–1553.
   PubMed Web of Science ®Google Scholar
• Qiang JK, Kim WB, Baibergenova A, et al. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg. 2017;21:131–136.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21:1855–1859.
   PubMed Web of Science ®Google Scholar
• Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6:9–13.
   PubMed Web of Science ®Google Scholar
• Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22(7):1300–1303.
   PubMed Web of Science ®Google Scholar
• Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with p155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46:25–28.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689.
   PubMed Web of Science ®Google Scholar
• Albayda J, Pinal-Fernandez I, Huang Y, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease and malignancy risk in dermatomyositis patients. Arthritis Care Res. 2017;69:1771–1776.
   PubMed Web of Science ®Google Scholar
• De Oliveira DS, Borges IBP, de Souza JM, et al. Exercise training attenuates insulin resistance and improves beta-cell function in patients with systemic autoimmune myopathies: a pilot study. Clin Rheumatol. 2019;38:3435–3442.
   PubMed Web of Science ®Google Scholar
• Wiesinger GF, Quittan M, Aringer M, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol. 1998;37:196–200.
   PubMedGoogle Scholar
• Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol. 1993;20:1340–1344.
   PubMed Web of Science ®Google Scholar
• Wiesinger GF, Quittan M, Graninger M, et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol. 1998;37:1338–1342.
   PubMedGoogle Scholar
• Alexanderson H, Stenstrom CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford). 1999;38:608–611.
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Stenstrom CH, Jenner G, et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol. 2000;29:295–301.
   PubMed Web of Science ®Google Scholar
• Heikkillä S, Viitanen JV, Kautiainen H, et al. Rehabilitation in myositis: preliminary study. Physiotherapy. 2001; 87:301–309.
   Google Scholar
• Karper WB, Hopewell R, Hodge M. Exercise program effects on one woman with dermatomyositis. Rehabil Nurs. 2001;26:129–131.
   PubMedGoogle Scholar
• Varju C, Petho E, Kutas R, et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil. 2003;17:83–87.
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheumatol. 2007;57:768–777.
   PubMed Web of Science ®Google Scholar
• Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol. 2007;57:694–702.
   PubMed Web of Science ®Google Scholar
• Nader GA, Dastmalchi M, Alexanderson H, et al. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med. 2010;16:455–464.
   PubMed Web of Science ®Google Scholar
• Alemo Munters L, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther. 2013;15:R83.
   PubMed Web of Science ®Google Scholar
• Alemo Munters L, Dastmalchi M, Andgren V, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken). 2013;65:1959–1968.
   PubMed Web of Science ®Google Scholar
• Mattar MA, Gualano B, Perandini LA, et al. Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis. Arthritis Res Ther. 2014;16:473.
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Munters LA, Dastmalchi M, et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis - a randomized controlled single-blinded study with a 2-year followup. J Rheumatol. 2014;41:1124–1132.
   PubMed Web of Science ®Google Scholar
• Bertolucci F, Neri R, Dalise S, et al. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. Eur J Phys Rehabil Med. 2014;50:161–169.
   PubMed Web of Science ®Google Scholar
• Munters LA, Loell I, Ossipova E, et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol. 2016;68:1738–1750.
   PubMed Web of Science ®Google Scholar
• Tiffreau V, Rannou F, Kopciuch F, et al. Postrehabilitation functional improvements in patients with inflammatory myopathies: the results of a randomized controlled trial. Arch Phys Med Rehabil. 2017;98:227–234.
   PubMed Web of Science ®Google Scholar
• Boehler JF, Hogarth MW, Barberio MD, et al. Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study. PLoS One. 2017;12:e0183292.
   PubMedGoogle Scholar
• Misse RG, Borges IBP, Santos AM, et al. Effects of exercise training on endothelial function, arterial structure, and physical conditioning in patients with systemic autoimmune myopathies: a case series study. Open J Rheumatol Autoimmun Dis. 2019;9:57.
   Google Scholar
• Winkelmann RK, Mulder DW, Lambert EH, et al. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc. 1968;43:545–556.
   PubMed Web of Science ®Google Scholar
• Matsubara S, Sawa Y, Takamori M, et al. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1994;57:1008.
   PubMed Web of Science ®Google Scholar
• Yanagisawa T, Sueishi M, Nawata Y, et al. Methylprednisolone pulse therapy in dermatomyositis. Dermatologica. 1983;167:47–51.
   PubMedGoogle Scholar
• Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol. 1999;455:349–357.
   PubMed Web of Science ®Google Scholar
• Raghu P, Manadan AM, Schumukler J, et al. Pulse dose methylprednisolone therapy for adult idiopathic inflammatory myopathy. Am J Ther. 2015;22:224–227.
   Web of Science ®Google Scholar
• Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1:99–102.
   PubMedGoogle Scholar
• Zieglschmid-Admas ME, Pandy AG, Cohen SB, et al. Treatment of dermatomyositis with methotrexate. J Am Acada Dermatol. 1995;32:754–757.
   PubMed Web of Science ®Google Scholar
• Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–387.
   PubMed Web of Science ®Google Scholar
• Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14:R22.
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Choy E, Gordon P, et al. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology (Oxford). 2015;54:1050–1055.
   PubMed Web of Science ®Google Scholar
• Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51:369–372.
   PubMed Web of Science ®Google Scholar
• Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheumatol. 1998;41:392–399.
   PubMed Web of Science ®Google Scholar
• Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27:2855–2859.
   PubMed Web of Science ®Google Scholar
• Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour post dose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35:254–259.
   PubMed Web of Science ®Google Scholar
• Takada K, Kishi J, Miyasaka N. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: A retrospective study. Mod Rheumatol. 2007;17:123–130.
   PubMedGoogle Scholar
• Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int. 2016;36:125–131.
   PubMed Web of Science ®Google Scholar
• Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65–69.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford). 2007;46:516–518.
   PubMed Web of Science ®Google Scholar
• Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44:386–389.
   PubMed Web of Science ®Google Scholar
• Olivo Pallo PA, De Souza FHC, Miossi R, et al. Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series. Adv Rheumatol. 2018;58:34.
   PubMedGoogle Scholar
• Tsuchiya H, Tsuno H, Inoue M, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014;24:694–696.
   PubMed Web of Science ®Google Scholar
• Koyama RVL, Braga TKK, da Silva Dias GA, et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. Clin Rheumatol. 2017;36:1919–1926.
   PubMed Web of Science ®Google Scholar
• Sangle VS, Sangle SR, D’Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis. 2008;67:723.
   PubMed Web of Science ®Google Scholar
• Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58:403–406.
   PubMed Web of Science ®Google Scholar
• Orden AO, Chuluyan JC, Colombini AC, et al. Leflunomide use in a cytomegalovirus infection of a patient with dermatomyositis. Rheumatol Int. 2012;32:273–275.
   PubMed Web of Science ®Google Scholar
• De Souza RC, De Souza FHC, Miossi R, et al. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. Clin Exp Rheumatol. 2017;35:1011–1013.
   PubMed Web of Science ®Google Scholar
• Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford). 2019;kez394.
   Google Scholar
• Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72:488–498.
   PubMed Web of Science ®Google Scholar
• Suzuka T, Kotani T, Takeuchi T, et al. Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. Int J Rheum Dis. 2019;22:303–313.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rhematology (Oxford). 2007;46:124–130.
   PubMed Web of Science ®Google Scholar
• Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21:1092–1097.
   PubMed Web of Science ®Google Scholar
• Göttfried I, Seeber A, Anegg B, et al. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol. 2000;10:29–35.
   PubMed Web of Science ®Google Scholar
• Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18:34–44.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Hara M, Koike T, et al. GB-0998 study group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22:382–393.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. RIM study group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–324.
   PubMed Web of Science ®Google Scholar
• Reed AM, Crowson CS, Hein M, et al. RIM study group. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015;16:257.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Guiguet M, Rigolet A, et al. efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase autoantibodies: an open-label, phase II trial. PLoS One. 2015;10:e0133702.
   PubMed Web of Science ®Google Scholar
• Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011;50:2206–2213.
   PubMed Web of Science ®Google Scholar
• Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33:1021–1026.
   PubMed Web of Science ®Google Scholar
• Sánchez-Fernández SÁ, Carrasco Fernández JA, Rojas Vargas LM. Efficacy of rituximab in dermatomyositis and polymyositis refractory to conventional therapy. Rheumatol Clin. 2013;9:117–119.
   Google Scholar
• Frikha F, Rigolet A, Behin A, et al. Efficacy of rituximab in refractory and relapsing myositis with anti-Jo-1 antibodies: a report of two cases. Rheumatology (Oxford). 2009;48:1166–1168.
   PubMed Web of Science ®Google Scholar
• Unger L, Kampf S, Lüthke K, et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014;53:1630–1638.
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheumatol. 2005;52:601–607.
   PubMed Web of Science ®Google Scholar
• De Souza FHC, Miossi R, De Moraes JCB, et al. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol. 2018;58:31.
   PubMedGoogle Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–1677.
   PubMed Web of Science ®Google Scholar
• Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33:1802–1804.
   PubMed Web of Science ®Google Scholar
• Amato AA, Tawil R, Kissel J, et al. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427–436.
   PubMed Web of Science ®Google Scholar
• Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77:55–62.
   PubMed Web of Science ®Google Scholar
• Kondo M, Murakawa Y, Matsumura T, et al. A Case of Overlap Syndrome Successfully Treated with Tocilizumab: a Hopeful Treatment Strategy for Refractory Dermatomyositis? Rheumatology (Oxford). 2014;53:1907–1908.
   PubMed Web of Science ®Google Scholar
• Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.
   PubMedGoogle Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–293.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Charlton D, Aggarwal R, et al. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology. 2019;58(6):1011–1015.
   PubMed Web of Science ®Google Scholar
• Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65(11):1456–1461.
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230–2237.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Aggarwal R, Oddis CV. Myositis in clinical practice-relevance of new antibodies. Best Pract Res Clin Rheumatol. 2018;32(6):887–890.
   PubMed Web of Science ®Google Scholar
• Marie E, Hachulla P, Chérin, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheumatol. 2002;47:614–622.
   PubMed Web of Science ®Google Scholar
• Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med. 2014;35:239–248.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–398.
   PubMedGoogle Scholar
• Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the antiCADM-140 antibody. Rheumatology (Oxford). 2010;49:433–440.
   PubMed Web of Science ®Google Scholar
• Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64:1602–1610.
   Web of Science ®Google Scholar
• Chaisson NF, Paik J, Orbai AM, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) (Baltimore). 2012;91:220–228.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;290797:2014.
   Google Scholar
• Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in us patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68:689–694.
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307–1315.
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25–34.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16:R138.
   PubMed Web of Science ®Google Scholar
• Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360–374.
   PubMed Web of Science ®Google Scholar
• Petri MH, Satoh M, Martin-Marquez BT, et al. Implications in the difference of anti-Mi2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013;15:R48.
   PubMed Web of Science ®Google Scholar
• Carvalho MICP, Shinjo SK. Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis. Adv Rheumatol. 2019;59:27.
   PubMedGoogle Scholar
• Hengstman GJ, Vree Egberts WT, Seeling HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006;65:242–245.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Reichlin M. The association between anti-Mi2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28:796–803.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1 gamma. Arthritis Rheum. 2013;65:2954–2962.
   PubMed Web of Science ®Google Scholar
• Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46:25–28.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–3689.
   PubMed Web of Science ®Google Scholar
• Albayda J, Pinal-Fernandez I, Huang Y, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease and malignancy risk in dermatomyositis patients. Arthritis Care Res. 2017;69:1771–1776.
   PubMed Web of Science ®Google Scholar
• Kröner PT, Tolaymat OA, Bowman AW, et al. Gastrointestinal manifestations of rheumatological diseases. Am J Gastroenterol. 2019;114:1441–1454.
   PubMed Web of Science ®Google Scholar
• Casal-Dominguez M, Pinal-Fernandez I, Mego M. et al. High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. Muscle Nerve. 2017;56:386–392.
   PubMed Web of Science ®Google Scholar
• Gadiparthi C, Hans A, Potts K, et al. Gastrointestinal and hepatic disease in the inflammatory myopathies. Rheum Dis Clin North Am. 2018;44:113–129.
   PubMed Web of Science ®Google Scholar
• Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–447.
   PubMed Web of Science ®Google Scholar